Browse Articles

Discover research articles across all indexed journals

Temporal trends in rural vs urban colon cancer mortality in Texas: A SEER database analysis from 2012 to 2021.

Journal of Clinical Oncology Ahmed Bashir Sukhera, Jorge Rodriguez Vazquez, Gloria Erazo et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.36

36 Background: Colorectal cancer is a major concern for the U.S. healthcare system, being the fourth most common cancer by incidence in the country with 152,810 cases in 2024. Measuring the burden this disease places on patients and health resources may serve to optimize our approach to the detection, management and resource allocation for combating this ailment. Methods: Our study is a population-based study cohort of colon cancer deaths in Texas. We queried the National Cancer Institute Surveillance, Epidemiology and End Results Program (SEER) for colon cancer deaths in Texas over the most recent available decade, 2012 through 2021. The National Center for Health Statistics Urban-Rural Classification Scheme was used to classify counties according to the 2013 US Census classification: urban (≥ 50,000) and rural (< 50,000). We calculated age-adjusted mortality rates (AAMRs) per 100,000 population using the direct standardization method based on the age group weights from the 2000 standard US population. Confidence intervals for AAMR were derived by estimating the standard error as the AAMR divided by square root of number of mortalities. Differences between AAMR were tested by comparing the 95% confidence intervals (95% CI) for the individual rates. The annual percent change (APC) in AAMR was tested using negative binomial regression. Subgroup analyses included age group, sex, and race/ethnicity. Results: Over the study period, 10.8% of the study population lived in rural areas and 89.2% lived in urban areas. A total of 33,591 colon-cancer deaths were reported during the study period with 5,423 (16.1%) in rural counties and 28,168 (83.9%) in urban counties. At the beginning of the study period the rural AAMR (13.9 [12.7 to 15.1]) was significantly higher than urban AAMR 12.1 [95% CI 11.7 - 12.6]). The rural AAMR rose significantly over the study period (APC 1.1% [95% CI 0.3% - 1.9%]; p = 0.0050) to AAMR 14.9 (95% CI 13.7 to 16.1). In contrast, the urban AAMR did not change over study period (APC -0.3% [95% CI -0.7 to 0.1]; p = 0.1444) and was equal to the initial AAMR 12.1 (95% CI 11.7 to 12.5). On subgroup analyses, males, people ages 25-64 years, Hispanics, Non-Hispanic Blacks, Non-Hispanic Asians, and Non-Hispanic Native Americans in rural areas each had significant and increasing trends in AAMR. Conclusions: Our analysis revealed an increase in AAMR in rural counties of Texas, reflecting a concerning trend with regard to colorectal cancer in this region. This may be due to higher poverty rates, lower level of education, more distance from healthcare facilities and difficulties with transportation faced by rural counties. Furthermore, rural areas also report higher rates of obesity and poor dietary habits. Rural areas also face a shortage of Primary Care Physicians (PCP’s), with metropolitan counties retaining 1.7 times as many PCP’s as rural counties, and 82.5% of counties without a PCP being rural.

Definitive local therapy in solitary liver metastatic anal squamous cell carcinoma.

Journal of Clinical Oncology Teerada Siripoon, Conor O'Donnell, Michael H. Storandt et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.5

5 Background: Metastatic anal squamous cell carcinoma is rare and associated with a poor prognosis. There is limited evidence on the impact of local interventions on survival outcomes in patients with metastatic disease. We aimed to evaluate the survival of patients with liver-only metastatic anal cancer following definitive local management of liver lesions. Methods: This is a single-institution retrospective cohort study of patients with liver-limited metastatic anal cancer who underwent curative-intent local therapy. Clinical characteristics were collected and analyzed. The Kaplan-Meier method was used to calculate disease-free survival (DFS) and overall survival (OS). Prognostic factors associated with DFS and OS were assessed using Cox-proportional hazards models. Results: Twenty-five patients were included, median age was 59 years, and 92% were female. None of the patients had known HIV infection, 92% had HPV-positive disease and 76% had metachronous liver metastases following locoregional disease. All patients received chemoradiation for the primary lesion Unilobar hepatic involvement was present in 76% of the patients, with 56% having a single metastatic lesion. Pre-intervention systemic therapy was provided to 52% of the patients, including 8 who received carboplatin and paclitaxel, with a median duration of 3 months and ORR of 69%. Definitive treatment of metastatic disease included surgical resection (60%), non-surgical interventions (20%), and multimodal therapy (20%). All patients had viable tumor in the pathological specimen. With a median follow-up of 22 months, median DFS was 7.3 months, and median OS was 51.3 months. An ECOG performance status of 2, poorly differentiated histology, and extrahepatic recurrence were identified as significant prognostic factors in the univariate analysis, but not in the multivariate analysis. Conclusions: Our results demonstrate potential for long-term survival in liver-limited metastatic anal squamous cell carcinoma amenable to local therapeutic intervention combined with systemic therapy. These findings warrant further prospective study of local therapy in oligometastatic anal cancer. Characteristics N=25 (%) Median number of liver metastases (range), lesions- 1- 2-3- >3 1 (1-20)14 (56)8 (32)3 (12) Median maximal diameter of liver metastases (range), cm 3 (0.9-11.9) Best response of liver metastases to chemotherapy (N=13)- Complete response- Partial response- Stable disease- Progressive disease 2 (15)7 (54)3 (23)1 (8) Surgical procedure (N=20)- Right/left hemi-hepatectomy- Segmentectomy- Wedge resection 4 (20)14 (70)2 (10) Non-surgical procedure (N=10)- Local ablation- Radiotherapy- Other 5 (50)3 (30)2 (20) Hepatic surgical margins (N=20)- Positive margins- Close margins (<1mm)- Negative margins 02 (10)18 (90) Recurrent disease- Yeso Intrahepatico Extrahepatic- No 20 (80)14 (70)6 (30)5 (20)

Temporal variations of metals and trace elements in tuna spines from the canary islands from 1990s to 2000s

Scientific Reports Eunice Vásquez-Domínguez, Enrique Lozano-Bilbao, Pedro J. Pascual Alayón et al. Feb 01, 2025 DOI: 10.1038/s41598-025-87116-2

Mutations in histones dysregulate copper homeostasis leading to defect in Sec61-dependent protein translocation mechanism in Saccharomyces cerevisiae

Journal of Biological Chemistry Santoshi Acharjee, Rajshree Pal, Smriti Anand et al. Feb 01, 2025 DOI: 10.1016/j.jbc.2025.108163

The incidence and risk of cardiovascular events among gastroesophageal cancer patients receiving immune-checkpoint inhibitors.

Journal of Clinical Oncology Furkan Bahar, Betul Ibis, Sena Cakir Colak et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.374

374 Background: Immune checkpoint inhibitors (ICIs) have been associated with an increased risk of cardiovascular events. However, these data were mostly derived from patients with lung cancer or melanoma. To date, there is limited data describing the incidence and risk of cardiovascular adverse events associated with the use of ICIs among patients with gastroesophageal cancers. Methods: We performed a propensity score-matched cohort study using the TriNetX Analytics Network database, which comprises de-identified data from over 120 participating institutions and 101 million individuals. We defined the ICI cohort as patients who received any of the ICIs and chemotherapy. We defined the control cohort as patients who received only chemotherapy but not an ICI. We matched 2 cohorts based on predetermined variables including age, race, gastroesophageal cancer-directed therapy, cardiovascular agents, underlying comorbidities, and surgical history. The outcomes were myocarditis, pericarditis, myocardial infarction, heart failure, cerebral ischemia/infarction, atrial fibrillation, conduction disorders, and venous thromboembolism (VTE). All outcomes were captured within 1-year of the start of ICI therapy and identified using the International Classification of Diseases (ICD)-10 codes. Results: We identified 2005 patients who received ICI and chemotherapy (ICI cohort) and 14048 patients who received chemotherapy only (control cohort). We matched 952 patients in 2 cohorts. The mean age was 62.8 ± 12.7 and 62.8 ± 12.3 for the ICI and chemotherapy cohorts, respectively. We observed a significant increase in cardiovascular events in the ICI cohort compared to the chemotherapy cohort. In particular, the risk of myocarditis (4 cases in the ICI cohort and no cases in the chemotherapy cohort), pericarditis (Hazard ratio (HR), 2.53 [95% CI: 1.52-4.19]), conduction disorders (HR, 1.64 [95% CI: 1.04-2.59]), and VTE (HR, 1.56 [95% CI: 1.17-2.10]) were higher in the ICI cohort than the chemotherapy cohort. Conclusions: The use of ICI was associated with an increased risk of cardiovascular events, particularly myocarditis, pericarditis, conduction disorders, and VTE among patients with gastroesophageal cancer. Further studies are needed to identify strategies to stratify patients at high risk of developing ICI-associated cardiovascular events. Outcomes ICI + Chemotherapy(ICI cohort) Chemotherapy only(Control cohort) Hazard ratio(95% CI) Cases At risk patients Cases At risk patients Myocarditis 4 952 0 952 - Pericarditis 52 952 21 952 2.53 (1.52-4.19) Myocardial infarction 18 952 12 952 1.49 (0.72-3.11) Cerebral Ischemia/Infarction 22 952 17 952 1.30 (0.69-2.44) Atrial fibrillation 56 952 48 952 1.16 (0.79-1.71) Conduction disorder 49 952 30 952 1.64 (1.04-2.59) Venous thromboembolism 112 952 73 952 1.56 (1.16-2.10) Heart Failure 118 952 114 952 1.04 (0.80-1.34)

Impact of time to surgery on outcomes in patients with advanced esophageal squamous cell carcinoma following neoadjuvant therapy: An exploratory analysis of phase III trial JCOG1109.

Journal of Clinical Oncology Ryosuke Kita, Ken Kato, Ryunosuke Machida et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.458

458 Background: JCOG1109, a multicenter three-arm phase III trial, evaluated three neoadjuvant treatment regimens for advanced esophageal squamous cell carcinoma (ESCC), cisplatin and 5-fluorouracil (CF), docetaxel, cisplatin, and 5-fluorouracil (DCF), and cisplatin, 5-fluorouracil, and radiation therapy (CF-RT). The trial demonstrated the superiority of neoadjuvant DCF therapy in improving overall survival (OS). This exploratory analysis investigates the impact of the interval time from completion of neoadjuvant therapy to surgery (time to surgery, TTS) on both short- and long-term outcomes across different neoadjuvant therapy regimens. Methods: This analysis included patients from JCOG1109 who underwent surgery after neoadjuvant therapy. Patients were categorized into four TTS subgroups within each arm, based on quartiles of the overall cohort. Short-term outcomes such as perioperative complications, as well as long-term outcomes including OS and progression-free survival (PFS) were evaluated across these TTS subgroups. Results: Of the 601 patients enrolled in JCOG1109, 546 patients proceeded to surgery following neoadjuvant therapy. The median TTS was 35 days (range: 16-81) for the CF arm, 38 days (range: 17-109) for the DCF arm, and 41 days (range: 14-98) for the CF-RT arm. Baseline characteristics were well-balanced across all TTS subgroups in each treatment arm. Short-term outcomes revealed that operative time and overall proportions of postoperative complications were comparable. However, in the CF-RT arm, a longer TTS was associated with increased blood loss (200 ml, 210 ml, 300 ml, 370 ml; p-value for trend test = 0.010) and tended to increase the risk of anastomotic leakage (6%, 7%, 14%, 18%; p-value for trend test = 0.073). No significant differences in OS or PFS were observed across TTS subgroups in any treatment arm, with hazard ratios indicating no clear trend toward improved or worsened long-term outcomes. Conclusions: The timing of surgery following neoadjuvant therapy does not appear to affect long-term prognosis in patients with advanced ESCC, irrespective of the neoadjuvant therapy regimen. However, for patients undergoing neoadjuvant CF-RT, earlier surgery may be advantageous in reducing the risk of increased surgical complexity and anastomotic leakage.

Safety and preliminary efficacy of ATG-022 in patients with advanced/metastatic gastric cancer (CLINCH).

Journal of Clinical Oncology Jinfeng Ma, Dan Cao, Qun Zhao et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.456

456 Background: ATG-022 is an antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN 18.2) tumor antigen broadly expressed in gastric and other solid tumors. ATG-022 consists of a humanized monoclonal antibody that binds to CLDN 18.2 with high affinity of sub-nM grade and a conjugated linker-payload VC-MMAE, demonstrating activity across a wide range of CLDN18.2 expression levels, including both high and low/ultra-low expression levels. Methods: The CLINCH study included dose escalation phase and dose expansion phase. In the dose escalation, patients(pts) with advanced solid tumors regardless of CLDN 18.2 expression received ATG-022 once every three weeks (0.3-3.0 mg/kg Q3W) to evaluate the safety, tolerability, and pharmacokinetics. CLDN 18.2-positive patients were enrolled in dose expansion to receive ATG-022 at recommended phase 2 doses (RP2D) to evaluate the efficacy and safety. The primary endpoints included dose-limiting toxicity (DLT) and adverse events (AEs). The efficacy endpoints included objective response rate (ORR) and disease control rate (DCR), evaluated per RECIST1.1 criteria. Results: As of Aug 21, 2024, 16 pts with advanced solid tumors, including 7 gastric cancer (GC), were treated with ATG-022 from 0.3 to 3.0 mg/kg in dose escalation, with 1 DLT of grade 3 nausea found at 3 mg/kg among 6 pts, and 21 GC pts were enrolled in dose expansion to receive RP2D of 2.4 mg/kg Q3W. Among all 37 pts, median age was 61 years. Baseline ECOG were 0 (9 pts) and 1 (28 pts); 33 (89.2%) pts had stage IV disease; 26 (70.3%) pts had received ≥ 2 prior lines of systemic therapy and 14 (37.8%) pts had prior anti-PD-1/L1 therapy. At 2.4 mg/kg in expansion, 3 (14.3%) pts had ≥ 1 Serious TRAEs; 8 (38.1%) pts had grade ≥ 3 TRAEs; the most common TRAEs included neutrophil count decreased (47.6%), nausea (38.1%) and white blood cell count decreased (33.3 %). In dose escalation, 7 GC pts were enrolled, including 3 CLDN 18.2-positive pts. One PR and 1 CR was observed in pts with GC at the dosage of 1.8 mg/kg and 2.4 mg/kg, respectively. Among 12 GC pts who had at least 1 tumor evaluation in dose expansion, 5 PR and 7 SD were observed, resulting in an ORR of 41.7%, and a DCR of 100%. One CR and 1 PR were observed among 3 GC pts receiving 2.4 mg/kg and with CLDN 18.2 expression < 2+, 5%. The Cmax of both total antibody and ADC drug is increased as dose increased from dose 0.3 – 3.0 mg/kg. No pronounced exposure accumulation was found after multiple dose treatment. Preliminary data showed Dose-Normalized AUC of MMAE for ATG-022 is comparable with other vcMMAE ADC drugs. Conclusions: ATG-022 demonstrated a manageable safety profile, comparable PK properties in current dosing levels, and encouraging preliminary antitumor effects in GC pts from high CLDN 18.2 expression to low CLDN 18.2 expression, suggesting further clinical investigation in pts with variable CLDN 18.2 expression. The enrollment of GC and other solid tumors are ongoing. Clinical trial information: NCT05718895 .

Vaccines for cancer prevention: exploring opportunities and navigating challenges

Nature Reviews Drug Discovery Michele Graciotti, Lana E. Kandalaft Feb 01, 2025 DOI: 10.1038/s41573-024-01081-5

High-Precision computational solutions for nonlinear evolution models in graphene sheets

Scientific Reports Mostafa M. A. Khater, Suleman H. Alfalqi, Aleksander Vokhmintsev Feb 01, 2025 DOI: 10.1038/s41598-025-85263-0

Abstract This study investigates the analytical solutions of a nonlinear evolution model governing the dynamics of graphene sheets, a material renowned for its exceptional electronic properties and versatile applications in nanotechnology. Three advanced analytical approaches-the Khater II (Khat II) method, the Khater III (Khat III) method, and the Generalized Rational (GRat) approach-are employed to derive exact solutions for this model with high precision. The accuracy and reliability of these solutions are validated by comparing them to numerical results obtained via He’s Variational Iteration (HVI) method, which serves as a benchmark for numerical verification. The analysis reveals a remarkable agreement between the analytical and numerical solutions, highlighting the robustness and effectiveness of the proposed methodologies. Furthermore, this study provides new insights into the nonlinear dynamics and physical properties of graphene sheets, while also identifying connections to other prominent nonlinear evolution equations. The innovative use of these analytical techniques offers practical frameworks for addressing complex nonlinear models in mathematical physics, thus advancing solution methodologies for such equations. This research contributes significantly to applied mathematics, material science, and nanotechnology by delivering accurate solutions and enhancing our understanding of graphene’s nonlinear behavior. Finally, the findings have far-reaching implications, offering potential applications in designing advanced materials with tailored properties to support technological advancements, thereby pushing the boundaries of nanotechnology and materials engineering.

Enhanced dynamic coupling in a nuclear receptor underlies ligand activity

Journal of Biological Chemistry Tracy Yu, Priscilla Villalona, Sabab Hasan Khan et al. Feb 01, 2025 DOI: 10.1016/j.jbc.2024.108081

Phase II trial of sintilimab in cancer of unknown primary.

Journal of Clinical Oncology Ryan W Huey, Kanwal Pratap Singh Raghav, Jeannelyn Estrella et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.825

825 Background: CUP is an aggressive rare malignancy accounting for 2-4% of all cancers. Beyond frontline therapy, predominantly systemic cytotoxic chemotherapy, no clear standard of care exists. Preliminary data suggests that immune-checkpoint inhibitors have encouraging activity in patients with CUP. Prior anti-PD1 agents have demonstrated response rates of 21-23%. We studied the role of sintilimab, an anti-PD1 antibody, in CUP. Methods: In this phase II study (NCT05024968)10 patients (of planned 40) were enrolled prior to closure of the study due to sponsor funding. Patients were eligible if they were refractory or intolerant to one line of systemic therapy or had a contraindication for cytotoxic chemotherapy. Patients received sintilimab 200 mg IV every 3 weeks. Paired tumor biopsies were collected for biomarker analysis. The primary endpoint was confirmed objective response rate (cORR) by RECISTv1.1 assessed by independent radiology review. Key secondary endpoints were safety, disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and Quality of Life (QOL). Median PFS and OS were calculated according to the Kaplan-Meier method. Adverse events (AEs) were assessed according to CTCAE v5.0. Results: Between 10/2021 and 2/2023, 10 patients were enrolled and treated. Median age was 65 years and 30% of patients were female. Seven (70%) had poorly differentiated carcinoma. Patients received a median of 1 line of therapy prior to enrollment. Median follow-up was 19.8 months. All patients were evaluable for toxicity and response. The cORR was 40% (95% CI, 12.2 to 73.8); one (10%) patient with a complete response and 3 (30%) with partial responses. The median DOR was 15.7 months. Three patients (30%) had Grade ≥ 3 (no grade 4/5) treatment-related AEs including 2 patients with sepsis and 1 patient with leukocytosis. Median PFS and OS were 4.4 months (95% CI, 2.0 to 25.4) and 25.4 months (95% CI, 4.0 to 27.4), respectively. Conclusions: Anti-PD1 therapy with Sintilimab demonstrated significant anti-tumor activity for select patients with refractory CUP with safety profile consistent with other anti-PD1 agents. Ongoing correlative studies may inform the role of biomarker selection for immunotherapy in CUP. Clinical trial information: NCT05024968 .

Postoperative exercise in gastric cancer patients undergoing gastrectomy: A randomized controlled trial.

Journal of Clinical Oncology Hyoung-Il Kim, Tae Ho Lee, Justin Y. Jeon Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.358

358 Background: Faster physical recovery after gastrectomy may lead to better physical and psychological health in patients with gastric cancer. Post-surgical exercise may prevent physical dysfunction and improve recovery, but its effects on physical function are not fully explored. Methods: In this trial, 52 gastric cancer patients (Stage 1-3) were randomly assigned to early postoperative exercise rehabilitation or usual care (1:1 ratio). Interventions Inpatient Supervised Exercise sessions were conducted for 15 minutes once a day on Postoperative Day (POD) 1 and 2 in the ward. Home-based Exercise involved 30-minute remote exercise sessions at home once a week following discharge, with additional recommendations for daily 30-minute sessions of low to moderate-intensity aerobic exercises and bodyweight exercises. Moreover, the exercise group was provided with an exercise log and instructional videos to record the duration of bodyweight exercises and aerobic exercises. Measurements were taken three times (baseline, POD3, and the first outpatient visit 1 month after surgery). The primary outcome was a Short Physical Performance Battery (SPPB), with secondary outcomes including grip strength, 30-second sit-to-stand (STS), body composition, C-reactive protein (CRP), and quality of life (QOL). Results: A total of 46 (88%) participants (mean [SD] age, 60.2 [12.24] years; 26 [57%] male) completed the trial. Compliance with intervention in-patient exercise was 96% and remote exercise was 79%. The significant difference in SPPB scores of 11.4±1.3 in the exercise group compared with 10.7±1.43 usual care group (mean difference, -1.09 score; 95%CI, -1.7 to -0.4; p=<.001). Moreover, there were significant differences between groups in the STS exercise group 14.3±2.8 usual care group 13.6±4.5 (mean difference, 1.86; 95%CI, -3.3 to -0.4; p=.028), and CRP in POD3 exercise group 66.9±40.73 usual care group 103.7±54.25 (mean difference, -22.54 score; 95%CI, -46.5 to 1.4; p=.016). However, there was no significant difference in grip strength, body composition, and QOL. Conclusions: Postoperative exercise presents as a beneficial strategy to enhance physical recovery in patients undergoing gastrectomy, improving key physical function markers and reducing inflammation. Clinical trial information: NCT06260293 .

Combination Immunotherapy for Advanced Melanoma—How to Choose?

Journal of Clinical Oncology Sophia Kreft, Paul Lorigan Feb 01, 2025 DOI: 10.1200/jco-24-02005

Antiviral target compound profile for pandemic preparedness

Nature Reviews Drug Discovery James F. Demarest, Ruxandra Draghia-Akli, Tomas Cihlar et al. Feb 01, 2025 DOI: 10.1038/s41573-024-01102-3

Enhancing safety in surface mine blasting operations with IoT based ground vibration monitoring and prediction system integrated with machine learning

Scientific Reports Mangalpady Aruna, Harsha Vardhan, Abhishek Kumar Tripathi et al. Feb 01, 2025 DOI: 10.1038/s41598-025-86827-w

mTOR signaling controls protein aggregation during heat stress and cellular aging in a translation- and Hsf1-independent manner

Journal of Biological Chemistry Arthur Fischbach, Per O. Widlund, Xinxin Hao et al. Feb 01, 2025 DOI: 10.1016/j.jbc.2025.108172

The expand indication of HER2 targeted therapies by monitoring of circulating tumor cells.

Journal of Clinical Oncology Koichi Suzuki Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.482

482 Background: Despite success in the HER2 targeted therapies for metastatic gastric cancer patients, the conventional assessment of HER2 status in tumor tissue specimens is still under debate. Methods: On-chip sorting system was used for the isolation of circulating tumor cells (CTCs). The fluorescence signal intensity > 50 is set to be a threshold value for distinguishing between positive and negative HER2 on CTCs. Epithelial mesenchymal transition (EMT) was assessed by the vimentin and cytokeratin. DNA was extracted from CTCs and applied to the cancer gene panel. Results: In 27 patients with metastatic gastric cancer, 13 patients showed HER2 positive in tumor tissues (Group A) who were treated with cytotoxic agents and HER2-targeted therapy while 14 patients exhibited negative and treated with cytotoxic agents. In these 14 patients, 8 patients showed HER2 positive (Group B) and 6 patients displayed HER2 negative (Group C) on CTCs. HER2 expression on CTCs was associated with EMT (p<0.001). Increased expression of EMT was seen in Group A and B, indicating they are likely to have metastasis. Group B exhibited worse PFS than others (13.8 M in A, 7.0 M in B and not reached in C, p=0.012). In addition, genomic analysis identified cancer gene mutations, some of which were involved in mechanisms underlying EMT and were shared between Group A and B. Considering HER2 expression on CTCs in Group B, an additional HER2-targeted therapy may be beneficial. Conclusions: Our study suggests that monitoring of circulating tumor cells leads to the expand indication of the HER2 targeted therapies in patients with metastatic gastric cancer.

Risk factors for relapse based on the molecular profiling of Japanese patients with stage II colorectal cancer.

Journal of Clinical Oncology Shunsuke Kasai, Keiichi Hatakeyama, Akio Shiomi et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.215

215 Background: The association between the molecular profiles and prognosis of Stage II colorectal cancer (CRC) remains unclear. This study aimed to evaluate the long-term outcomes of Stage II CRC based on the molecular profiling and to examine the risk factors for relapse. Methods: We retrospectively enrolled Japanese patients with pStage II CRC without pre- and/or postoperative adjuvant therapy and whose surgically resected specimens were evaluated using gene expression and whole exome analyses from January 2014 to December 2018. We evaluated the 5-year overall survival (OS) and relapse-free survival (RFS), and examined the risk factors for RFS. Results: We evaluated 322 patients with pStage II CRC, including 126 (39.1%) with right colon cancer, 133 (41.3%) with left colon cancer and 63 (19.6%) with rectal cancer. There were 87 patients (27.0%) with pT4, 175 (54.3%) with venous invasion, 120 (37.3%) with lymphatic invasion, and 68 (21.1%) with perineural invasion. Whole exome analyses revealed that there were 48 patients (14.9%) with MSI-High, and the presence of mutations in key genes for colorectal cancer development was as follows: APC , 245 (76.1%); TP53 , 208 (64.6%); KRAS , 134 (6.5%); PIK3CA , 64 (19.9%); FBXW7 , 27 (8.4%); and BRAF , 21 (6.5%). The 5-year OS and RFS rates were 98.0% and 90.7%, respectively. According to the consensus molecular subtype (CMS) classification based on gene expression, 76 patients (23.6%) had CMS4 and a significantly lower RFS than the other patients (5-year RFS: 83.8% vs. 92.9%, p=0.017). The independent risk factors for RFS were perineural invasion (Hazard ratio [HR] 5.316, p<0.001) and CMS4 (HR 2.399, p=0.020). Conclusions: Molecular profiling of Stage II CRC to assess the risk factors for relapse may contribute to the indication and drug selection for postoperative adjuvant chemotherapy and lead to personalized treatment to improve prognosis.

A single institution retrospective study evaluating mitomycin dosing during chemoradiation in anal squamous cell carcinoma.

Journal of Clinical Oncology Jenny Gong, Emily Simon, J. Eva Selfridge et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.7

7 Background: Mitomycin (MMC) is used concurrently during chemoradiation (CRT) treatment for non-metastatic anal squamous cell carcinoma (SCCA). The most effective dosing of MMC is not established, and due to concerns for tolerability, many have adopted a dose-reduction strategy. This study evaluates differences in treatment response and recurrence between MMC dosing in this setting. Methods: Demographics, age, smoking history, staging, and treatment history were collected for patients with non-metastatic SCCA treated with CRT from January 2011-September 2024 at a tertiary cancer center. Chi-square analyses compared categorical variables, and ANOVA tests were used to compare treatment response and recurrence between 3 MMC doses (12mg/m 2 x 1 dose with cap of 20mg, 10mg/m 2 x 2 doses, 10mg/m 2 x 1 dose). Results: There were 124 patients, 6 of whom were excluded due to lack of follow up. Of the 118 included, 70% were female, 16% Black, 3% Hispanic/Latino, and 58% current/former smokers. Median age was 61 years (31-98). Thirty-three (28%) pts were treated with MMC 12mg/m 2 , 71 (60%) with 10mg/m 2 x2 doses, and 14 (12%) with 10mg/m 2 x1 dose. Stage I included 18% of 12mg/m2, 7% of 10mg/m 2 x2 doses, and 7% of 10mg/m 2 x1 dose; stage II included 18% of 12mg/m2, 37% of 10mg/m 2 x2 doses, and 50% of 10mg/m 2 x1 dose; stage III included 64% of 12mg/m2, 56% of 10mg/m 2 x2 doses, and 43% of 10mg/m 2 x1 dose. A total of 39.7% were treated with MMC/capecitabine and 60.3% with MMC/fluorouracil. Complete response was achieved in 91% receiving the 12mg/m 2 , 75% receiving 10mg/m 2 x2 dose, and 71% receiving 10mg/m 2 x1 dose (p=0.13, Table 1). Using logistic regression with MMC dose, stage, age, and smoking status as independent predictors, the odds of achieving complete response were lower in 10mg/m 2 x2 doses (p=0.03) and 10mg/m 2 x1 dose (p=0.03) compared to 12mg/m 2 . Local, regional, or metastatic recurrence occurred in 15% of pts receiving 12mg/m 2 , 17% of 10mg/m 2 x2 doses, and 7% of 10mg/m 2 x1 dose. No significant difference was seen in local (p=0.52), regional (p=0.93), metastatic (p=0.87), or overall recurrence (p=0.65) between the MMC doses. Conclusions: Odds of achieving complete response was greater with 12mg/m 2 dosing. Local, regional, and metastatic recurrence were similar among the different MMC dosing cohorts. Differences in tolerance and side effects should be delineated to guide individualized dosing of MMC.

Nutritional and anti-nutritional evaluation of injera made from Sorghum, Rice, Teff, and Flaxseed flours using D-optimal mixture design

Scientific Reports Moges Amtataw, Estifanos Kassahun, Solomon Tibebu et al. Feb 01, 2025 DOI: 10.1038/s41598-025-88407-4